{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T14:23:13Z","timestamp":1770646993268,"version":"3.49.0"},"reference-count":10,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:00:00Z","timestamp":1602806400000},"content-version":"unspecified","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Nilasha Ghosh","award":["NIH\/NCATS UL1-TR-0023849"],"award-info":[{"award-number":["NIH\/NCATS UL1-TR-0023849"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,10,2]]},"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:p>Immune checkpoint inhibitors (ICI) block negative regulatory molecules, such as CTLA-4, PD-1 and PD-L1, in order to mount an antitumor response. T cells are important for antiviral defense, but it is not known whether patients with cancer treated with ICI are more or less vulnerable to viral infections such as COVID-19. Furthermore, immunosuppressive treatment of immune-related adverse events (irAE) may also impact infection risk. Rheumatic irAEs are often persistent, and can require long-term treatment with immunosuppressive agents. The aim of this study was to determine the incidence of COVID-19 infection and assess changes in ICI and immunosuppressive medication use among patients enrolled in a prospective rheumatic irAE registry during the height of the COVID-19 pandemic. On April 16 2020, following the \u2018surge\u2019 of COVID-19 infections in the New York Tri-State area, we sent a 23-question survey to 88 living patients enrolled in a single institutional registry of patients with rheumatic irAE. Questions addressed current cancer and rheumatic irAE status, ICI and immunosuppressant medication use, history of COVID-19 symptoms and\/or diagnosed infection. A follow-up survey was sent out 6 weeks later. Sixty-five (74%) patients completed the survey. Mean age was 63 years, 59% were female, 70% had received anti-PD-(L)1 monotherapy and 80% had had an irAE affecting their joints. Six patients (10%) had definite or probable COVID-19, but all recovered uneventfully, including two still on ICI and on low-to-moderate dose prednisone. Of the 25 on ICI within the last 6 months, seven (28%) had their ICI held due to the pandemic. In patients on immunosuppression for irAE, none had changes made to those medications as a result of the pandemic. The incidence of COVID-19 was no higher in patients still on ICI. Ten percent of rheumatic irAE patients developed COVID-19 during the NY Tri-state \u2018surge\u2019 of March\u2013April 2020. Oncologists held ICI in a quarter of the patients still on them, particularly women, those on anti-PD-(L)1 monotherapy, and those who had had a good cancer response. The incidence of COVID-19 was no higher on patients still on ICI. None of the patients on disease-modifying antirheumatic drugs or biological immunosuppressive medications developed COVID-19.<\/jats:p>","DOI":"10.1136\/jitc-2020-001550","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T17:45:41Z","timestamp":1602870341000},"page":"e001550","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8799-9309","authenticated-orcid":false,"given":"Nilasha","family":"Ghosh","sequence":"first","affiliation":[{"name":"Hospital for Special Surgery Division of Rheumatology, New York, New York, USA"},{"name":"Weill Cornell Medicine, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aidan","family":"Tirpack","sequence":"additional","affiliation":[{"name":"Hospital for Special Surgery Division of Rheumatology, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karmela K","family":"Chan","sequence":"additional","affiliation":[{"name":"Hospital for Special Surgery Division of Rheumatology, New York, New York, USA"},{"name":"Weill Cornell Medicine, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne R","family":"Bass","sequence":"additional","affiliation":[{"name":"Hospital for Special Surgery Division of Rheumatology, New York, New York, USA"},{"name":"Weill Cornell Medicine, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,10,16]]},"reference":[{"key":"2025100301125353000_8.2.e001550.1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m736"},{"key":"2025100301125353000_8.2.e001550.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216109"},{"key":"2025100301125353000_8.2.e001550.3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00487"},{"key":"2025100301125353000_8.2.e001550.4","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2019.00207","article-title":"The PD-1\/PD-L1 axis and virus infections: a delicate balance","volume":"9","author":"Sch\u00f6nrich","year":"2019","journal-title":"Front Cell Infect Microbiol"},{"key":"2025100301125353000_8.2.e001550.5","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/apt.15449","article-title":"Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects","volume":"50","author":"Lombardi","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2025100301125353000_8.2.e001550.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30309-0"},{"key":"2025100301125353000_8.2.e001550.7","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0596"},{"key":"2025100301125353000_8.2.e001550.8","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/s41591-020-0979-0","article-title":"Determinants of COVID-19 disease severity in patients with cancer","volume":"26","author":"Robilotti","year":"2020","journal-title":"Nat Med"},{"key":"2025100301125353000_8.2.e001550.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217871"},{"key":"2025100301125353000_8.2.e001550.10","doi-asserted-by":"crossref","unstructured":"Stadlbauer D , Tan J , Jiang K , et al . Seroconversion of a city: longitudinal monitoring of SARS-CoV-2 seroprevalence in New York City. medRxiv 2020.","DOI":"10.1101\/2020.06.28.20142190"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-001550","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:12:59Z","timestamp":1759479179000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-001550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":10,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,10,16]]},"published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1136\/jitc-2020-001550"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-001550","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}